Suppr超能文献

[抑制试验在抗甲状腺药物治疗过程控制中的应用:一种体内核医学程序的复兴?]

[The suppression test in the control of the course of antithyroid drug therapy: renaissance of an in vivo nuclear medicine procedure?].

作者信息

Reiners C, Becker W, Börner W

出版信息

Nuklearmedizin. 1985 Jun;24(3):135-40.

PMID:2414740
Abstract

Measurements of thyroidal suppressibility by thyroid hormones belong to the diagnostic program in nuclear medicine for more than 30 years. Suppression tests are used in follow-up of antithyroidal treatment to predict remission or relapse of hyperthyroidism. Recently, the number of publications dealing with suppression tests has been increasing. Apparently, non-suppressibility of the thyroid after antithyroidal treatment for about 1 year corresponds to a rate of relapse of about 70% whereas in the case of a positive suppression test, the relapse rate amounts to about 20% only. The diagnostic procedures described in the literature are different with respect to radiopharmaceuticals, activity doses, thyroid hormone suppression and, above all, to the time of uptake measurements. After a critical discussion of the literature, a modern diagnostic procedure for the suppression test is proposed using 123I or 99mTc and a computer-assisted gamma camera.

摘要

甲状腺激素对甲状腺抑制性的测量属于核医学诊断程序已有30多年。抑制试验用于抗甲状腺治疗的随访,以预测甲亢的缓解或复发。最近,有关抑制试验的出版物数量一直在增加。显然,抗甲状腺治疗约1年后甲状腺不被抑制对应着约70%的复发率,而在抑制试验阳性的情况下,复发率仅约为20%。文献中描述的诊断程序在放射性药物、活性剂量、甲状腺激素抑制方面,尤其是在摄取测量时间方面存在差异。在对文献进行批判性讨论后,提出了一种使用123I或99mTc以及计算机辅助γ相机的现代抑制试验诊断程序。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验